Biotech
4 Early-Stage Rare Disease Startups to Watch in 2026
DealBio tracks early-stage rare disease startups across Europe and North America. Here are 4 worth watching in 2026, spanning cystic fibrosis, genetically defined autism, inherited skin disease and Pompe disease.
- Rare Disease
- Therapeutics
- Gene Therapy
- Drug Delivery
Rare-disease drug development is increasingly focused on defined patient groups, mutations and delivery barriers. Even in established treatment categories, gaps remain in mutation coverage, tissue delivery, durability and immune response.
The four startups address those gaps through different therapeutic strategies, from small molecules and gene editing to targeted delivery. Each is built around a defined biological problem rather than a broad disease label.
At a Glance
- VG2D PharmaFrance2024CFTR modulation for cystic fibrosis
- Translation-XSwitzerland2026Small molecules for genetically defined autism
- EpithelicaGermany2025Topical base editing for inherited skin disease
- NanoZymeXSwitzerland2026Lipid nanoparticle enzyme delivery for Pompe disease
Developing a new oral therapy for cystic fibrosis.
- Country
France- Founded
- 2024
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why VG2D Pharma stands out
VG2D Pharma is developing a mutation-broadening cystic fibrosis program around patented small molecules licensed from SATT Nord and the University of Reims. The technology was developed by its scientific co-founders and is intended to extend treatment across additional mutations in CFTR.
The program has completed preclinical proof-of-concept work in vitro and in vivo. VG2D Pharma has also received public innovation support through the i-Lab competition and Bpifrance.
What VG2D Pharma is building
VG2D Pharma is developing oral small molecules designed to modulate CFTR while also addressing inflammatory biology associated with cystic fibrosis.
The program is being developed as an oral treatment for patients whose mutations, response, tolerability or access leave them poorly served by current CFTR modulators.
Developing oral small molecules for core symptoms of genetically defined autism.
- Country
Switzerland- Founded
- 2026
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why Translation-X stands out
Translation-X focuses on genetically defined autism syndromes, where the underlying biology and patient population can be more clearly specified. Nature-published work showed that inhibiting MNK1/2 restored social behaviour in an animal model, supporting the target.
The founding team combines autism neuroscience with drug-development experience. Chemistry co-founder Guido Koch spent more than two decades at Novartis and contributed to two marketed drugs and seven clinical candidates. Translation-X has raised CHF 1 million across grants and equity.
What Translation-X is building
Translation-X is developing brain-penetrant oral small molecules that selectively inhibit MNK1/2. Its first indications include genetic forms of autism such as Fragile X syndrome, Phelan-McDermid syndrome and tuberous sclerosis complex.
The initial program focuses on genetic conditions in which MNK1/2 is strongly implicated, giving Translation-X a defined patient population for early development.
Developing topical non-viral gene-editing therapies for inherited skin diseases.
- Country
Germany- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
- Founders
Why Epithelica stands out
Epithelica’s preclinical program is supported by a 2026 Cell Stem Cell study in human models of ARCI. The study corrected a mutation in TGM1 and restored about 30% of normal transglutaminase 1 activity.
The TGM1 program has orphan drug designation in the United States and Europe. Two PCT filings cover the editing method and skin delivery. In repeat-dose testing, the lipid nanoparticles and genetic cargo remained localized to the skin, with no systemic distribution detected.
What Epithelica is building
Epithelica combines a fractional dermatology laser, topical lipid nanoparticles and an RNA-based base editor. The laser creates temporary micropores so the nanoparticles can reach living epidermal cells and correct the disease-causing DNA locally.
The local-delivery approach is designed to avoid viral vectors and cell transplantation while targeting skin-renewing basal cells, with the aim of durable correction without systemic exposure.
Developing lipid nanoparticle enzyme therapies for Pompe and other rare diseases.
- Country
- Switzerland
- Founded
- 2026
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why NanoZymeX stands out
NanoZymeX is addressing two limitations of enzyme replacement therapy: inefficient delivery to skeletal muscle and immune responses to the replacement enzyme. Its peer-reviewed work reported more than a five-fold reduction in antibody response versus free enzyme formulations.
The startup has secured about CHF 1.4 million in grants and institutional support and was selected for Venture Leaders Biotech 2026. The platform originates from University of Basel research and starts from enzyme replacement therapy, an established treatment modality, while changing how the enzyme is delivered.
What NanoZymeX is building
NanoZymeX packages therapeutic enzymes inside proprietary lipid nanoparticles. Its lead program delivers acid alpha-glucosidase for Pompe disease, with the particles designed to increase uptake in skeletal muscle and diaphragm and protect the enzyme from immune recognition.
The same lipid nanoparticle platform is designed to carry other replacement enzymes, supporting expansion beyond Pompe disease into additional enzyme-deficiency disorders.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Rare-disease precision is moving beyond patient segmentation
Across the four startups, precision appears in different forms: patient selection, mutation coverage, local gene editing and tissue delivery. Each approach is designed around a clearly defined biological problem.
The common pattern is narrower therapeutic development around a specific mechanism or patient group. That can make the target population and development path more clearly defined while placing greater emphasis on translation, manufacturing and market size.
Methodology
DealBio selected these startups from its coverage of early-stage health and longevity startups, focusing on rare-disease startups using different targeted treatment strategies. The selection spans small molecules, precision neurology, topical gene editing and nanoparticle-enabled enzyme replacement.
DealBio builds its Startup Briefs using publicly available startup materials, ecosystem sources, market references and professional profiles.